Yellow Tomorrow The place to be

Orano Med

Targeted lead-212 Alpha Therapy for cancer treatment

Orano subsidiary Orano Med’s ambition is to develop a robust portfolio of cancer treatments that combine the unique properties of lead-212 with targeting molecules. This technique, best known as Targeted Alpha Therapy, opens up promising prospects for patients whose treatment has reached a dead end.